BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for
Depression with Anxiety
Posted : Thu, 17 Apr 2008 20:32:15 GMT
SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. (BCI), a
biopharmaceutical company utilizing its platform technology to
identify and develop compounds that promote the growth of new neurons
for the treatment of central nervous system (CNS) diseases, announced
today that it has initiated a Phase 2a clinical trial with its lead
product candidate, BCI-540, for the treatment of depression with
anxiety.
"We are encouraged by the enthusiasm expressed by our clinical
investigators who view BCI-540 as a potential alternative to today's
widely prescribed treatments for depression," noted Carrolee Barlow,
M.D., Ph.D., Chief Scientific Officer at BCI. "Current therapies
directly impact serotonin levels causing many unpleasant side
effects, however we have shown that BCI-540 directly impacts
neurogenesis without affecting serotonin levels. We are excited about
the potential of this compound to change the way mood disorders are
treated."
The twelve-week randomized double-blind, placebo-controlled study
will evaluate safety, efficacy and tolerability of BCI-540 to
determine whether 80 mg given once or three times daily is effective
in the treatment of depression with anxiety versus placebo.
"BCI is utilizing our understanding of the power of neurogenesis
coupled with our proprietary neurogenic platform technology to
identify a strong portfolio of clinical candidates, such as BCI-540,
that we plan to move into the clinic this year," said Jim Schoeneck,
CEO at BCI. "Moving BCI-540 into the clinic is an important milestone
and we are now actively enrolling patients and anticipate completing
enrollment by the end of this year."
About BrainCells Inc.
BrainCells Inc. (BCI) is a San Diego-based drug discovery and
development company that is applying its proprietary neurogenesis
platform technology to identify and reposition compounds for the
treatment of central nervous system (CNS) diseases. Neurogenesis is
the process by which endogenous stem cells in the adult human brain
produce new brain tissue, including neurons. With its predictive
screening platform, BCI can direct the selection and development of
neurogenic compounds, increasing the opportunity for successful
clinical trials in a variety of CNS indications. For more
information, visit http://www.braincel
Media Contact:
BrainCells Inc.
Kim Richards
Porter Novelli Life Sciences
619-849-5377
krichards@pnlifesci
BrainCells Inc.
http://www.earthtim
phase-2,357457.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment